Livforsakringsbolaget Skandia Omsesidigt Cuts Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Livforsakringsbolaget Skandia Omsesidigt drastically reduced its holdings in United Therapeutics by 98.1% in the second quarter, selling 20,600 shares and ending up with only 400 shares valued at $115,000.
• Several institutional investors increased their stakes in United Therapeutics, with notable increases from Hohimer Wealth Management LLC and Applied Finance Capital Management LLC during the first quarter.
• Analysts have varied price targets for United Therapeutics, ranging from $330 to $564, with nine analysts rating the stock as a Buy and four as a Hold, resulting in an average target price of $438.85.

Livforsakringsbolaget Skandia Omsesidigt reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 98.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 400 shares of the biotechnology company's stock after selling 20,600 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in United Therapeutics were worth $115,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of UTHR. XTX Topco Ltd acquired a new stake in shares of United Therapeutics in the 1st quarter valued at about $313,000. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares during the last quarter. LPL Financial LLC boosted its stake in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new position in United Therapeutics during the 1st quarter valued at about $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. UBS Group lifted their price target on United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday, September 4th. Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday, September 3rd. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 10th. Finally, HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $438.85.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the firm's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $400.17, for a total transaction of $1,600,680.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares of the company's stock, valued at approximately $52,022.10. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Judy D. Olian sold 1,800 shares of the firm's stock in a transaction on Friday, September 19th. The shares were sold at an average price of $415.43, for a total transaction of $747,774.00. Following the transaction, the director directly owned 5,045 shares of the company's stock, valued at $2,095,844.35. The trade was a 26.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 172,116 shares of company stock worth $63,256,557. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

United Therapeutics stock traded up $7.70 during midday trading on Friday, reaching $417.57. 1,940,191 shares of the company traded hands, compared to its average volume of 874,340. The firm has a market capitalization of $18.84 billion, a price-to-earnings ratio of 16.30, a price-to-earnings-growth ratio of 6.37 and a beta of 0.62. The business has a 50 day moving average of $329.55 and a two-hundred day moving average of $310.67. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the company earned $5.85 EPS. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.